查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1589740

末期肾病市场：按治疗、诊断和最终用户分类 - 全球预测 2025-2030

End Stage Renal Disease Market by Treatment (Dialysis, Transplantation), Diagnosis (Blood Tests, Imaging Tests, Kidney Sample Removal For Testing), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年末期肾病市场价值为462.9亿美元，预计2024年将达到530.9亿美元，复合年增长率为14.80%，到2030年将达到1216.5亿美元。

末期肾病 (ESRD) 是慢性肾臟病的最后阶段，也是最严重的阶段，此时肾臟功能仅达到正常功能的 10% 至 15% 左右。 ESRD 的治疗需要维持生命，其中透析和肾臟移植至关重要。主要用途包括血液透析机、腹膜透析和移植，最终用途包括医院、诊所和独立透析中心。市场成长主要是由高血压和糖尿病盛行率上升和患者数量增加所推动的。家庭透析治疗解决方案等技术进步和政府改善医疗基础设施的努力正在推动需求。为新兴市场开发用于透析的远端医疗和远端监控技术以及负担得起的透析设备的机会也在扩大。主要研究兴趣包括加强与医疗保健提供者的伙伴关係以及投资人工肾臟研究。

主要市场统计
基准年[2023] 462.9亿美元
预测年份 [2024] 530.9亿美元
预测年份 [2030] 1216.5亿美元
复合年增长率（%） 14.80%

然而，成长并非没有挑战。市场扩张受到透析和移植成本高昂以及获得合适器官的机会有限的限制。监管障碍和严格的合规要求使情况更加复杂。此外，缺乏熟练的专业人才也是一大障碍。创新包括携带式和可穿戴式透析机、人工智慧在预测性患者照护中的集成，以及用于肾臟修復的再生医学技术。减少透析副作用和改善长期患者预后的研究也可能提供竞争优势。该市场的特点是技术快速发展以及现有和新兴参与者之间的竞争日益激烈。对公司来说，策略联盟和併购被认为是提高市场占有率的潜在途径。专注于以患者为中心的解决方案和成本效率的公司可能在这个重要的医疗保健领域拥有竞争优势。

市场动态：快速发展的末期肾病市场的关键市场洞察

供需的动态交互作用正在改变末期肾病市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 慢性肾臟病病患者增加
    • 患有高血压和糖尿病的老年人口不断增加
    • 生活方式的改变和加工食品的消费增加
  • 市场限制因素
    • 併发症的风险
  • 市场机会
    • 介绍新的技术增强产品
    • 增加对研发活动的投资以及製造商之间的合作
  • 市场挑战
    • 新医疗设备核准的严格监管通讯协定

波特五力：驾驭末期肾臟病市场的策略工具

波特的「五力」框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解末期肾臟病市场的外部影响

外部宏观环境因素在塑造终末期肾病市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解末期肾病市场的竞争格局

末期肾病市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来发现自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵末期肾病市场供应商的绩效评估

FPNV 定位矩阵是评估末期肾臟病市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了终末期肾病市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对终末期肾病市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 慢性肾臟病病患者增加
      • 患有高血压和糖尿病的老年人越来越多
      • 生活方式的改变和加工食品消费的增加
    • 抑制因素
      • 併发症的风险
    • 机会
      • 新技术增强产品介绍
      • 增加对研发活动的投资以及製造商之间的合作
    • 任务
      • 新设备核准的严格监管通讯协定
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依治疗分类的末期肾臟病市场

  • 透析
    • 血液透析机
    • 腹膜透析
    • 穿戴式人工肾
  • 移植

第七章 末期肾病诊断市场

  • 验血
  • 影像检查
  • 收集肾臟样本进行检测
  • 尿液检查

第八章末期肾病市场：依最终用户分类

  • 透析中心
  • 医院/诊所
  • 研究/学术机构

第九章美洲末期肾病市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太终末期肾病市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲末期肾臟病市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Amgen Inc.
  • Asahi Kasei Medical Co., Ltd.
  • AstraZeneca
  • B. Braun SE
  • Baxter International, Inc.
  • Becton, Dickinson and Company
  • Bristol-Myers Squibb Company
  • Davita Healthcare Partners Inc.
  • Fresenius Medical Care AG & Co. KGaA
  • GlaxoSmithKline PLC
  • Kissei Pharmaceutical Co., Ltd
  • Medtronic PLC
  • Nikkiso Co., Ltd.
  • Pfizer Inc.
  • Sanofi SA
Product Code: MRR-DA46DD749C68

The End Stage Renal Disease Market was valued at USD 46.29 billion in 2023, expected to reach USD 53.09 billion in 2024, and is projected to grow at a CAGR of 14.80%, to USD 121.65 billion by 2030.

End Stage Renal Disease (ESRD) represents the final and most severe stage of chronic kidney disease, where kidneys can only function at roughly 10-15% of their normal capacity. The necessity of treatments for ESRD is driven by their life-sustaining nature, where dialysis or kidney transplantation becomes imperative. The primary applications include hemodialysis, peritoneal dialysis, and transplantation, with the end-use scope encompassing hospitals, clinics, and independent dialysis centers. Market growth is largely influenced by rising incidences of hypertension and diabetes, leading to an increased patient base. Advancements in technology, such as home-based dialysis solutions, and government initiatives toward improved healthcare infrastructure amplify demand. Opportunities abound in telehealth and remote monitoring technologies for dialysis, as well as in developing affordable dialysis equipment for emerging markets. Key recommendations include enhancing partnerships with healthcare providers and investing in research for artificial kidneys.

KEY MARKET STATISTICS
Base Year [2023] USD 46.29 billion
Estimated Year [2024] USD 53.09 billion
Forecast Year [2030] USD 121.65 billion
CAGR (%) 14.80%

However, growth is not without challenges. High costs of dialysis and transplants, coupled with limited access to suitable organs, constrain market expansion. Regulatory hurdles and stringent compliance requirements further complicate the landscape. Additionally, the scarcity of skilled professionals poses a significant barrier. Innovation should target portable and wearable dialysis devices, integration of AI in predictive patient care, and regenerative medicine techniques for kidney repair. Research into reducing the side effects of dialysis and improving long-term patient outcomes can also offer competitive advantages. The market is characterized by rapidly evolving technologies and heightened competition among established and emergent players. For businesses, strategic alliances, and mergers & acquisitions stand out as potential paths to strengthen market presence. Companies that focus on patient-centric solutions and cost-effectiveness will likely command a competitive edge in this crucial healthcare segment.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving End Stage Renal Disease Market

The End Stage Renal Disease Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Proliferation in number of people suffering from chronic kidney disease
    • Growing geriatric population with hypertension and diabetes
    • Increasing lifestyle changes and consumption of processed food
  • Market Restraints
    • Risk of complications
  • Market Opportunities
    • Introduction of new technologically enhanced products
    • Increasing investment in research and development activities coupled with collaborations among manufacturers
  • Market Challenges
    • Stringent regulatory protocols for the approval of new devices

Porter's Five Forces: A Strategic Tool for Navigating the End Stage Renal Disease Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the End Stage Renal Disease Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the End Stage Renal Disease Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the End Stage Renal Disease Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the End Stage Renal Disease Market

A detailed market share analysis in the End Stage Renal Disease Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the End Stage Renal Disease Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the End Stage Renal Disease Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the End Stage Renal Disease Market

A strategic analysis of the End Stage Renal Disease Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the End Stage Renal Disease Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., Asahi Kasei Medical Co., Ltd., AstraZeneca, B. Braun SE, Baxter International, Inc., Becton, Dickinson and Company, Bristol-Myers Squibb Company, Davita Healthcare Partners Inc., Fresenius Medical Care AG & Co. KGaA, GlaxoSmithKline PLC, Kissei Pharmaceutical Co., Ltd, Medtronic PLC, Nikkiso Co., Ltd., Pfizer Inc., and Sanofi SA.

Market Segmentation & Coverage

This research report categorizes the End Stage Renal Disease Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment, market is studied across Dialysis and Transplantation. The Dialysis is further studied across Hemodialysis, Peritoneal Dialysis, and Wearable Artificial Kidney.
  • Based on Diagnosis, market is studied across Blood Tests, Imaging Tests, Kidney Sample Removal For Testing, and Urine Tests.
  • Based on End-User, market is studied across Dialysis Centres, Hospital & Clinics, and Research & Academic Institutes.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Proliferation in number of people suffering from chronic kidney disease
      • 5.1.1.2. Growing geriatric population with hypertension and diabetes
      • 5.1.1.3. Increasing lifestyle changes and consumption of processed food
    • 5.1.2. Restraints
      • 5.1.2.1. Risk of complications
    • 5.1.3. Opportunities
      • 5.1.3.1. Introduction of new technologically enhanced products
      • 5.1.3.2. Increasing investment in research and development activities coupled with collaborations among manufacturers
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory protocols for the approval of new devices
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. End Stage Renal Disease Market, by Treatment

  • 6.1. Introduction
  • 6.2. Dialysis
    • 6.2.1. Hemodialysis
    • 6.2.2. Peritoneal Dialysis
    • 6.2.3. Wearable Artificial Kidney
  • 6.3. Transplantation

7. End Stage Renal Disease Market, by Diagnosis

  • 7.1. Introduction
  • 7.2. Blood Tests
  • 7.3. Imaging Tests
  • 7.4. Kidney Sample Removal For Testing
  • 7.5. Urine Tests

8. End Stage Renal Disease Market, by End-User

  • 8.1. Introduction
  • 8.2. Dialysis Centres
  • 8.3. Hospital & Clinics
  • 8.4. Research & Academic Institutes

9. Americas End Stage Renal Disease Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific End Stage Renal Disease Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa End Stage Renal Disease Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Amgen Inc.
  • 2. Asahi Kasei Medical Co., Ltd.
  • 3. AstraZeneca
  • 4. B. Braun SE
  • 5. Baxter International, Inc.
  • 6. Becton, Dickinson and Company
  • 7. Bristol-Myers Squibb Company
  • 8. Davita Healthcare Partners Inc.
  • 9. Fresenius Medical Care AG & Co. KGaA
  • 10. GlaxoSmithKline PLC
  • 11. Kissei Pharmaceutical Co., Ltd
  • 12. Medtronic PLC
  • 13. Nikkiso Co., Ltd.
  • 14. Pfizer Inc.
  • 15. Sanofi SA

LIST OF FIGURES

  • FIGURE 1. END STAGE RENAL DISEASE MARKET RESEARCH PROCESS
  • FIGURE 2. END STAGE RENAL DISEASE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. END STAGE RENAL DISEASE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. END STAGE RENAL DISEASE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. END STAGE RENAL DISEASE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. END STAGE RENAL DISEASE MARKET DYNAMICS
  • TABLE 7. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY WEARABLE ARTIFICIAL KIDNEY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY KIDNEY SAMPLE REMOVAL FOR TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY URINE TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS CENTRES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOSPITAL & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 191. END STAGE RENAL DISEASE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 192. END STAGE RENAL DISEASE MARKET, FPNV POSITIONING MATRIX, 2023